DPP4 and gallbladder disorder: Faillie et al.’s (2016) comparative study on 71,369 T2DM patients, of whom 853 were hospitalized for bile duct and gallbladder disease (incidence rate per 1000 person-years, 3.7; 95% CI, 3.5–4.0), assessed the association of the use of GLP-1 analogues and DPP-4 inhibitors and the increased risk of bile duct and gallbladder diseases.